Jim Hughes Email

Head Information Technology . Dynavax Technologies

Current Roles

Employees:
423
Revenue:
$91.8M
About
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company?s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development.
Dynavax Technologies Address
2100 Powell Street
null, null
Dynavax Technologies Email

Past Companies

Dynavax TechnologiesHead Of Information Technology
GrifolsSenior Director, Global IT PMO and Process Improvement
Novartis Diagnostics and GrifolsDirector, NA Diagnostics IT and M&A Program Manager

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.